

08/21/01

A

08/20/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification  
of this Application:  
Class 514 Subclass \_\_\_\_\_

Prior Application:  
Examiner V. Balasubramanian  
Group Art Unit 1624

Attorney's  
Docket  
No. 45990-ZAA/JPW/ADM

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

August 20, 2001

J1033 U.S. PTO  
09/933106  
08/20/01

S I R:

This is a request for filing a X CONTINUATION

       DIVISIONAL        CONTINUATION-IN-PART application under

X 37 C.F.R. §1.53(b)        37 C.F.R. §1.53(d)<sup>1</sup>, of pending prior application

Serial No. 09/398,861 filed on September 20, 1999 of

Wai C. Wong, Yoon T. Jeon, T.G. Murali Dhar and Charles Gluchowski for  
inventor(s)

IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND USES THEREOF

Title of Invention

1. X Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy.
2. X A verified statement to establish small entity status under 37 C.F.R. §1.9 and 1.27  
       is enclosed.  
X was filed in the prior application and such status is still proper and desired (37 C.F.R. §1.28(a)).

3. X The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT

	NUMBER FILED		NUMBER EXTRA*		RATE		FEE		
					SMALL ENTITY	OTHER ENTITY		SMALL ENTITY	OTHER ENTITY
Total Claims	16-20	=	0	X	\$ 9	\$ 18	=	\$ 0	\$
Independent Claims	3-3	=	0	X	\$ 40	\$ 80	=	\$ 0	\$
Multiple Dependent Claims Presented: <u>  X  </u> Yes <u>      </u> No					\$ 135	\$ 270	=	\$ 135	\$
*If the difference in Col. 1 is less than zero, enter "0" in					BASIC FEE			\$355	\$ 710
					TOTAL FEE			\$ 490	\$

\*If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

<sup>1</sup> filing an application pursuant to this section expressly abandons the parent application.

10. 9. 8. 7. 6. 5. 4. 3. 2. 1.

4. X The Commissioner is hereby authorized to charge payment of the following fees associated with this application or credit any overpayment to Deposit Account No. 03-3125.

X Any patent application processing fees under 37 C.F.R. §1.17.

X Three copies of this sheet are enclosed.

Cancel claims \_\_\_\_\_.

\_\_\_\_ Sheet(s) of \_\_\_\_ informal \_\_\_\_ formal drawing(s) is/  
are enclosed.

11. \_\_\_\_\_ Priority of application No. \_\_\_\_\_ filed on \_\_\_\_\_  
 \_\_\_\_\_ in \_\_\_\_\_  
 \_\_\_\_\_ (country)  
 is claimed under 37 U.S.C. §119.

12.     X     The prior application is assigned of record to  
Synaptic Pharmaceutical Corporation.

14. X The power of attorney in the prior application is to:

John P. White (Reg. No. 28.678); Thomas F. Moran (Reg. No. 16.579); Norman H. Zivin (Reg. No. 25.385); Ivan S. Kavrukov (Reg. No. 25.161); Christopher C. Dunham (Reg. No. 22.031); Robert D. Katz (Reg. No. 30.141); Peter J. Phillips (Reg. No. 29.691); Richard S. Milner (Reg. No. 33.970); Albert Wai-Kit Chan (Reg. No. 36.479); Matthew B. Tropper (Reg. No. 37.457); Robert T. Maldonado (Reg. 38.232); Mary Anne P. Tanner (Reg. No. 40.197); and Mary Catherine DiNunzio (Reg. No. 37.306)

Name: Wai C. , et al.  
Serial No.: Not Yet Known  
Filed: Herewith

Cont/Div./FWC  
Page 3

- (a)   X   The power appears in the original papers in the prior application.
- (b)        Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- (c)   X   Address all future communications to:  
(May only be completed by applicant,  
or attorney or agent of record.)

John P. White

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

15.   X  

Also enclosed Express Mail Certificate of Mailing No.

EL525962992US

dated August 20, 2001

16.   X  

I hereby verify that the attached papers are a true copy of prior application Serial No. 09/398,861 as originally filed on September 20, 1999.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statement and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

August 20, 2001

Date

Signature

John P. White, Reg. No. 28,678

       INVENTOR(S)  
       ASSIGNEE OF COMPLETE INTEREST  
  X   ATTORNEY OR AGENT OF RECORD  
       FILED UNDER 37 C.F.R. §1.34(a)

Address of Signator:

Cooper & Dunham LLP

1185 Avenue of the Americas

New York, New York 10036

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Wai C. Wong, Yoon T. Jeon, T.G. Murali  
Dhar and Charles Gluchowski  
U.S. Serial No.: Not Yet Known  
Filed : Herewith  
For : IMIDAZOLE AND IMIDAZOLINE DERIVATIVES AND  
USES THEREOF

1185 Ave of the Americas  
New York, New York 10036  
August 20, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Attn: Box Patent Application

Sir:


**EXPRESS MAIL CERTIFICATE OF MAILING**  
**FOR ABOVE-IDENTIFIED APPLICATION**

"Express Mail" Mailing Label Number: EL525962992US  
Date of deposit: August 20, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, Attn. Box Patent Application.

Printed Name Samuel Khabib

Respectfully submitted,

  
John P. White  
Registration No. 28,678  
Attorney for Applicant(s)  
Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400